pharma · Dravet syndrome · Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
Biocodex
Biocodex is a pharma organization headquartered in GENTILLY, FR. Primary therapeutic focus areas include Dravet syndrome, Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3), Non-constipated Irritable Bowel Syn
Gentilly, FR HQ
1953 Founded
1,648 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gentilly, FR
- Founded
- 1953
- Employees
- 1,648
- Programs
- 5
- Drugs
- 15
- Patents
- 25
STP226
Phase 3 · small molecule · Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
STP226 for Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3) is a Phase 3 program (small_molecule) at Biocodex with 1 ClinicalTrials.gov record(s).
Internal code STP226
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biocodex
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
- Status
- active
- Trials
- 1